Quantification and monitoring of PET/CT data in multicentre trials: The Swiss SAKK 56/07 trial experience

Gnesin, Silvano; Deshayes, Emmanuel; Camus, Fabrice; Dunet, Vincent; Prior, John O.; Verdun, Francis R.

doi:10.1016/j.mednuc.2017.06.004

Cited by 7 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the beginning of this study, we introduced our own PET/quality control program used in several national and international PET studies [11] until our center participated to the quality control program by the European Association of Nuclear Medicine (EANM)-EARL as PET/CT Center of Excellence in October 2011, for which we have been accredited each year so far. For 18 F-FDG PET/CT, patients fasted for at least 6 h before and blood glucose was measured before administration of the radiotracer and required to be < 8.5 mmol/L, otherwise the scan was rescheduled.…”

Section: Baseline 18 F-fdg Pet/ct and Derived Parametersmentioning

confidence: 99%

18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer

et al. 2020

View full text Add to dashboard Cite

Background: Although 18 F-FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F-FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis. Methods: All patients (n = 86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005 and 2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor's maximal Standardized Uptake Value (SUV max), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses. Results: High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max > 8.25 g/mL (p < 0.001), TLG > 41.7 (p < 0.001) and MTV > 10.70 cm 3 (p < 0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p = 0.030), particularly in squamous cell cancer. Conclusions: Baseline 18 F-FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

show abstract

Section: Baseline 18 F-fdg Pet/ct and Derived Parametersmentioning

confidence: 99%

18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Hence, it does not take into account other parameters like dose calibrator, injected activity, serum glucose level, and post-injection time. To minimize variability of these parameters, multi-center participants must meet accreditation requirements that should include, for instance, the use of traceable sources for calibration of their dose calibrator, and similar patient preparation [7,19].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of PET quantitation accuracy among multiple discovery IQ PET/CT systems via NEMA image quality test

et al. 2020

View full text Add to dashboard Cite

Introduction: Quantitative imaging biomarkers are becoming usual in oncology for assessing therapy response. The harmonization of image quantitation reporting has become of utmost importance due to the multi-center trials increase. The NEMA image quality test is often considered for the evaluation of quantitation and is more accurate with a radioactive solid phantom that reduces variability. The goal of this project is to determine the level of variability among imaging centers if acquisition and imaging protocol parameters are left to the center's preference while all other parameters are fixed including the scanner type. Methods: A NEMA-IQ phantom filled with radioactive 68 Ge solid resin was imaged in five clinical sites throughout Europe. Sites reconstructed data with OSEM and BSREM algorithms applying the sites' clinical parameters. Images were analyzed according with the NEMA-NU2-2012 standard using the manufacturerprovided NEMA tools to calculate contrast recovery (CR) and background variability (BV) for each sphere and the lung error (LE) estimation. In addition, a 18 F-filled NEMA-IQ phantom was also evaluated to obtain a gauge for variability among centers when the sites were provided with identical specific instructions for acquisition and reconstruction protocol (the aggregate of data from 12 additional sites is presented). Results: The data using the 68 Ge solid phantom showed no statistical differences among different sites, proving a very good reproducibility among the PET center models even if dispersion of data is higher with OSEM compared to BSREM. Furthermore, BSREM shows better CR and comparable BV, while LE is slightly reduced. Two centers exhibit significant differences in CR and BV values for the 18 F NEMA NU2-2012 experiments; these outlier results are explained.

show abstract

“…Since the beginning of this study, we introduced our own PET/quality control program used in several national and international PET studies [11] until our center participated to the quality control program by the European Association of Nuclear Medicine (EANM)-EARL as PET/CT Center of Excellence in October 2011, for which we have been accredited each year so far. For 18 F-FDG PET/CT, patients fasted for at least 6 hours before and blood glucose was measured before administration of the radiotracer and required to be <8.5 mmol/L, otherwise the scan was rescheduled.…”

Section: Baseline 18 F-fdg Pet/ct and Derived Parametersmentioning

confidence: 99%

18 F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

Mantziari

Pomoni

Prior

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Although 18 F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.Methods All patients (n=86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUV max ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.Results High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm 3 (p<0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer.Conclusions Baseline 18 F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

show abstract

Quantification and monitoring of PET/CT data in multicentre trials: The Swiss SAKK 56/07 trial experience

Cited by 7 publications

References 15 publications

18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer

18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer

Evaluation of PET quantitation accuracy among multiple discovery IQ PET/CT systems via NEMA image quality test

18 F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

Contact Info

Product

Resources

About